Precision treatment in breast cancer: Leveraging genetic interactions

Cai-Jin Lin; Xin Hu; Zhi-Ming Shao; Yi-Zhou Jiang

doi:10.1002/ctm2.70407

Clinical and Translational Medicine ›› 2025, Vol. 15 ›› Issue (7) : e70407 DOI: 10.1002/ctm2.70407

COMMENTARY

Precision treatment in breast cancer: Leveraging genetic interactions

Author information +

History +

PDF

Cite this article

Download citation ▾

Cai-Jin Lin, Xin Hu, Zhi-Ming Shao, Yi-Zhou Jiang. Precision treatment in breast cancer: Leveraging genetic interactions. Clinical and Translational Medicine, 2025, 15(7): e70407 DOI:10.1002/ctm2.70407

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Wang D, Liu B, Zhang Z. Accelerating the understanding of cancer biology through the lens of genomics. Cell. 2023; 186(8): 1755-1771.

[2]	Jiang Y-Z, Ma D, Jin X, et al. Integrated multiomic profiling of breast cancer in the Chinese population reveals patient stratification and therapeutic vulnerabilities. Nat Cancer. 2024; 5(4): 673-690.

[3]	Mosele MF, Westphalen CB, Stenzinger A, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2024; 35(7): 588-606.

[4]	Goutsouliak K, Veeraraghavan J, Sethunath V, et al. Towards personalized treatment for early stage HER2-positive breast cancer. Nat Rev Clin Oncol. 2020; 17(4): 233-250.

[5]	Chen C, Lin C-J, Pei Y-C, et al. Comprehensive genomic profiling of breast cancers characterizes germline-somatic mutation interactions mediating therapeutic vulnerabilities. Cell Discov. 2023; 9(1): 125.

[6]	Fulton-Ward T, Middleton G. The impact of genomic context on outcomes of solid cancer patients treated with genotype-matched targeted therapies: a comprehensive review. Ann Oncol. 2023; 34(12): 1113-1130.

[7]	Mina M, Iyer A, Tavernari D, Raynaud F, Ciriello G. Discovering functional evolutionary dependencies in human cancers. Nat Genet. 2020; 52(11): 1198-1207.

[8]	Hanker AB, Brown BP, Meiler J, et al. Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity. Cancer Cell. 2021; 39(8): 1099-1114 e1098.

[9]	Liu R, Rizzo S, Waliany S, et al. Systematic pan-cancer analysis of mutation-treatment interactions using large real-world clinicogenomics data. Nat Med. 2022; 28(8): 1656-1661.

[10]	Lin CJ, Jin X, Ma D, et al. Genetic interactions reveal distinct biological and therapeutic implications in breast cancer. Cancer Cell. 2024; 42(4): 701-719. e712.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.